
Please try another search
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, alpha-radiation therapy candidate designed for the direct targeting of cancers that have spread to body cavities, like the peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company was incorporated in 2010 and is based in Oslo, Norway.
Name | Age | Since | Title |
---|---|---|---|
Anne Cecile Alvik | - | - | Head of Quality Assurance & Employee Representative Director |
Markus Dietrich | - | - | Board Observer |
Johan Haggblad | 67 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review